Roferon is indicated for Follicular Non-Hodgkin Lymphoma

Subtype:

Follicular Lymphoma (FL)

License:

EMA

Class:

Interferon alpha

Newly Diagnosed

SmPChttps://www.medicines.org.uk/emc/medicine/1730 

1. Approved Labelling 

Roferon is indicated for Follicular Non-Hodgkin Lymphoma.

2. Treatment Regimen

Roferon-A should be administered concomitantly to a conventional chemotherapy regimen (such as the combination of cyclophosphamide, prednisone, vincristine and doxorubicin) according to a schedule such as 6 million IU/m2 given subcutaneously from day 22 to day 26 of each 28-day cycle.

3. AE/Warnings

Please see section 4.4 of the SmPC

 

 

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.